Cargando…

Inebilizumab, a B Cell-Depleting Anti-CD19 Antibody for the Treatment of Autoimmune Neurological Diseases: Insights from Preclinical Studies

Exaggerated or inappropriate responses by B cells are an important feature in many types of autoimmune neurological diseases. The recent success of B-cell depletion in the treatment of multiple sclerosis (MS) has stimulated the development of novel B-cell-targeting therapies with the potential for i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Ding, Gallagher, Sandra, Monson, Nancy L., Herbst, Ronald, Wang, Yue
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2016
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5184780/ https://www.ncbi.nlm.nih.gov/pubmed/27886126 http://dx.doi.org/10.3390/jcm5120107

Ejemplares similares

Inebilizumab: First Approval
por: Frampton, James E.
Publicado: (2020)

Germinal Center B Cell Depletion Diminishes CD4(+) Follicular T Helper Cells in Autoimmune Mice
por: Yusuf, Isharat, et al.
Publicado: (2014)

Inebilizumab: A Review in Neuromyelitis Optica Spectrum Disorder
por: Nie, Tina, et al.
Publicado: (2022)

Correction to: Inebilizumab: A Review in Neuromyelitis Optica Spectrum Disorder
por: Nie, Tina, et al.
Publicado: (2022)

Long-term efficacy and safety of inebilizumab in neuromyelitis optica spectrum disorder: Analysis of aquaporin-4–immunoglobulin G–seropositive participants taking inebilizumab for ⩾4 years in the N-MOmentum trial
por: Rensel, Mary, et al.
Publicado: (2021)

Disability Outcomes in the N-MOmentum Trial of Inebilizumab in Neuromyelitis Optica Spectrum Disorder
por: Marignier, Romain, et al.
Publicado: (2021)

Sensitivity analysis of the primary endpoint from the N-MOmentum study of inebilizumab in NMOSD
por: Cree, Bruce AC, et al.
Publicado: (2021)

Pharmacodynamic modelling and exposure–response assessment of inebilizumab in subjects with neuromyelitis optica spectrum disorders
por: Yan, Li, et al.
Publicado: (2022)

Efficacy and Safety of Inebilizumab in IgG4-Related Disease: Protocol for a Randomized Controlled Trial
por: Perugino, Cory, et al.
Publicado: (2023)

International Delphi Consensus on the Management of AQP4-IgG+ NMOSD: Recommendations for Eculizumab, Inebilizumab, and Satralizumab
por: Paul, Friedemann, et al.
Publicado: (2023)

Population Pharmacokinetic Modeling of Inebilizumab in Subjects with Neuromyelitis Optica Spectrum Disorders, Systemic Sclerosis, or Relapsing Multiple Sclerosis
por: Yan, Li, et al.
Publicado: (2021)

Safety and tolerability of inebilizumab (MEDI-551), an anti-CD19 monoclonal antibody, in patients with relapsing forms of multiple sclerosis: Results from a phase 1 randomised, placebo-controlled, escalating intravenous and subcutaneous dose study
por: Agius, Mark A, et al.
Publicado: (2017)

Intrathecal anti-CD20 efficiently depletes meningeal B cells in CNS autoimmunity
por: Lehmann-Horn, Klaus, et al.
Publicado: (2014)

COVID‐19 vaccine‐readiness for anti‐CD20‐depleting therapy in autoimmune diseases
por: Baker, D., et al.
Publicado: (2020)

Targeting BMI‐1 to deplete antibody‐secreting cells in autoimmunity
por: Polmear, Jack, et al.
Publicado: (2023)

B cell depletion therapies in autoimmune disease: advances and mechanistic insights
por: Lee, Dennis S. W., et al.
Publicado: (2020)

Long-term safety of rituximab induced peripheral B-cell depletion in autoimmune neurological diseases
por: Memon, Anza B., et al.
Publicado: (2018)

Preclinical efficacy and toxicity studies of a highly specific chimeric anti‐CD47 antibody
por: Xu, Zhiqiang, et al.
Publicado: (2021)

Anti-CD8 monoclonal antibody-mediated depletion alters the phenotype and behavior of surviving CD8+ T cells
por: Cross, Eric W., et al.
Publicado: (2019)

Longitudinal COVID-19 immune trajectories in patients with neurological autoimmunity on anti-CD20 therapy
por: Bazzi, Sam A., et al.
Publicado: (2022)

An anti-CTLA-4 heavy chain–only antibody with enhanced T(reg) depletion shows excellent preclinical efficacy and safety profile
por: Gan, Xin, et al.
Publicado: (2022)

B-cell subpopulations in humans and their differential susceptibility to depletion with anti-CD20 monoclonal antibodies
por: Leandro, Maria J
Publicado: (2013)

Preanalytic depletion of medicinal anti-CD38 antibody from patient plasma for immunohematology testing
por: Ehrend, Elisabeth, et al.
Publicado: (2021)

B cell depletion in autoimmune disease
por: Gorman, Claire, et al.
Publicado: (2003)

A Preclinical Population Pharmacokinetic Model for Anti‐CD20/CD3 T‐Cell‐Dependent Bispecific Antibodies
por: Ferl, Gregory Z., et al.
Publicado: (2018)

Anti‐CD20 monoclonal antibody therapy in postpartum women with neurological conditions
por: Anderson, Annika, et al.
Publicado: (2023)

Serum neurofilament light chain levels at attack predict post-attack disability worsening and are mitigated by inebilizumab: analysis of four potential biomarkers in neuromyelitis optica spectrum disorder
por: Aktas, Orhan, et al.
Publicado: (2023)

Autoimmune Neurologic Disorders
por: Živković, Saša
Publicado: (2011)

The case for autoimmune neurology
por: Dalmau, Josep
Publicado: (2017)

Neurochondrin neurological autoimmunity
por: Shelly, Shahar, et al.
Publicado: (2019)

Next-generation anti-CD20 monoclonal antibodies in autoimmune disease treatment
por: Du, Fanny Huynh, et al.
Publicado: (2017)

Is There a Future for Anti-CD38 Antibody Therapy in Systemic Autoimmune Diseases?
por: Benfaremo, Devis, et al.
Publicado: (2019)

Review of an Anti-CD20 Monoclonal Antibody for the Treatment of Autoimmune Diseases of the Skin
por: Ly, Sophia, et al.
Publicado: (2023)

A Depleting Anti-CD45 Monoclonal Antibody as Isolated Conditioning for Bone Marrow Transplantation in the Rat
por: Jäger, Mark D., et al.
Publicado: (2016)

Gender issues of antibody-mediated diseases in neurology: (NMOSD/autoimmune encephalitis/MG)
por: Altintas, Ayse, et al.
Publicado: (2020)

Overlapping Autoimmune Neurological Syndrome: A Case Report of Triple-Positive Antibody
por: Bonner, Kyle, et al.
Publicado: (2022)

Utility of Protein Microarrays for Detection of Classified and Novel Antibodies in Autoimmune Neurologic Disease
por: McKeon, Andrew, et al.
Publicado: (2023)

Therapeutic Advances in Diabetes, Autoimmune, and Neurological Diseases
por: Liu, Jinsha, et al.
Publicado: (2021)

Over ten-year insulin independence following single allogeneic islet transplant without T-cell depleting antibody induction
por: Williams, Jack, et al.
Publicado: (2018)

B cell depletion therapies in autoimmune diseases: Monoclonal antibodies or chimeric antigen receptor-based therapy?
por: Zhang, Zheng, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ur0n4veau8aep0h1imifjsp5om